# NCT00045968 (NCT00045968)

> Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

No report yet. It can be ordered.

- Drugs tested: DCVax-L
- Indication: newly diagnosed glioblastoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00045968
- Phase: PHASE3
- Status: UNKNOWN
- Sponsor: Northwest Biotherapeutics
- Conditions: Glioblastoma Multiforme; Glioblastoma; GBM; Grade IV Astrocytoma; Glioma; Brain Cancer; Brain Tumor
- Interventions: Dendritic cell immunotherapy
- Enrollment: 348
- Primary outcome: The primary objective of this study is to compare overall survival (OS) between patients randomized to DCVax-L and control patients from comparable, contemporaneous trials who received standard of care therapy only, in newly diagnosed glioblastoma.

## Indexed commentary on NCT00045968 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct00045968